论文部分内容阅读
目的:探讨阿德福韦酯联合黄芪颗粒治疗慢性乙型肝炎的临床疗效及对患者血清ALT和总胆红素水平的影响。方法:80例慢性乙型肝炎患者随机分为观察组和对照组各40例。对照组给予阿德福韦酯治疗,观察组在对照组基础上加用黄芪颗粒治疗。两组疗程均为24周。疗程结束后比较两组患者的临床疗效、血清丙氨酸转氨酶(ALT)与总胆红素水平变化、HBe Ag转阴率、HBV-DNA转阴率及药品不良反应发生情况。结果:观察组治疗后总有效率显著高于对照组(P<0.05);治疗后,两组患者血清ALT、总胆红素水平均较治疗前显著降低(P<0.05),且治疗后观察组血清ALT、总胆红素水平显著低于对照组(P<0.05);观察组HBe Ag转阴率显著高于对照组(P<0.05),HBV-DNA转阴率略高于对照组,但差异无统计学意义意义(P>0.05);两组药品不良反应发生率比较,差异无统计学意义(P>0.05)。结论:阿德福韦酯联合黄芪颗粒治疗慢性乙型肝炎的临床疗效显著,能显著降低患者血清ALT和总胆红素水平,提高HBe Ag转阴率,且不良反应少,值得临床推广。
Objective: To investigate the clinical efficacy of adefovir dipivoxil combined with Astragalus Granules in treating chronic hepatitis B and its effects on serum ALT and total bilirubin levels. Methods: Eighty patients with chronic hepatitis B were randomly divided into observation group and control group, 40 cases each. The control group was treated with adefovir dipivoxil, and the observation group was treated with astragalus membranaceus on the basis of the control group. Two courses of treatment were 24 weeks. After treatment, the clinical efficacy, serum ALT and total bilirubin levels, HBeAg negative rate, HBV-DNA negative rate and adverse drug reactions were compared between the two groups. Results: After treatment, the total effective rate in the observation group was significantly higher than that in the control group (P <0.05). After treatment, serum ALT and total bilirubin levels in the two groups were significantly lower than those before treatment (P <0.05) The levels of serum ALT and total bilirubin were significantly lower than those of the control group (P <0.05). The negative rate of HBe Ag in the observation group was significantly higher than that of the control group (P <0.05) But the difference was not statistically significant (P> 0.05). There was no significant difference between the two groups in the incidence of adverse drug reactions (P> 0.05). Conclusion: Adefovir dipivoxil combined with Astragalus Granules in the treatment of chronic hepatitis B has significant clinical curative effect, which can significantly reduce the level of serum ALT and total bilirubin, increase the negative rate of HBeAg, and have fewer side effects. It is worthy of clinical promotion.